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Abstract Infants with hypoplastic left heart syndrome
(HLHS) are at risk for interstage morbidity and mortality,
especially between the first and second surgical stages after
the Norwood and hybrid procedures. This study compared
the morbidity and mortality of patients treated by either the
Norwood or the hybrid procedure for HLHS between the first
and second stages who were undergoing interstage moni-
toring. Between October 2008 and December 2011, 26
infants (14 boys) with HLHS (n = 16) and other univen-
tricular heart malformations with aortic arch anomaly
(n = 10) were scheduled for interstage monitoring after
Norwood I (n = 12) and hybrid (n = 14) procedures. Three
infants (11.5 %) died after first-stage palliation (one hybrid
patient and two Norwood patients), and three infants
(11.5 %) died after second-stage palliation (two hybrid
patients and one Norwood patient) (p = 0.83), all after early
second-stage surgery (\90 days). The Norwood I and hybrid
procedures did not differ in terms of overall mortality (23 %)
(three hybrid and three Norwood patients; p = 1.00). Seven
infants (26.9 %) could not be discharged from the hospital
due to hemodynamic instability and were referred for early
second-stage surgery (\90 days). After the first stage, the
invasive reevaluation rate before discharge was high
(53.8 %), with cardiac catheterizations for 8 of 14 patients
after the hybrid procedure and for 6 of 12 patients after the
Norwood procedure (p = 0.69). A total of 11 reinterventions
were performed (eight by catheter and three by surgery). Of
the eight catheter reinterventions, five were performed for
hybrid patients (p = 0.22). For 14 infants, 89 days (range
10–177 days) of interstage monitoring were scheduled. One
infant (3.9 %) died during the interstage monitoring. The
findings showed a breach of the physiologic criteria for
interstage monitoring in seven infants (50 %) after 10 days
(range 4–68 days) (five hybrid and two Norwood patients),
leading to rehospitalization and catheterization for six
patients (four hybrid and two Norwood patients), requiring
interventions for two patients (patent arterial duct stent
dilation, and atrial septal defect stenting, all for hybrid
patients). Overall, three of the seven patients with red flag
events of interstage monitoring were candidates for early
second-stage surgery. In conclusion, morbidity among
infants treated for HLHS remains high, either before or after
hospital discharge, emphasizing the need of interstage
monitoring programs. Despite retrograde aortic flow in
infants with HLHS after the hybrid procedure, the mortality
rate was comparable between the two groups. Mortality
occurs after early second-stage surgery (\90 days).
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Introduction
Hypoplastic left heart syndrome (HLHS) is one of the most
complex types of congenital heart disease. The last decade
has seen continuous efforts to optimize treatment for
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patients with HLHS. The Norwood procedure has been the
classical surgical treatment for HLHS, but meanwhile, the
hybrid procedure has been used as an alternative approach,
with comparable results [1, 11].
The hybrid procedure combines cardiac surgery (bilateral
pulmonary branch artery banding) and catheter intervention
with stenting of the patent arterial duct (PDA) and balloon
dilation of the atrial septal defect (ASD) [1, 11]. Nevertheless,
patients after first-stage palliation with either the Norwood or
the hybrid procedure remain at risk for interstage morbidity
and mortality [4, 10, 17, 24]. Therefore, interstage monitoring
has proved to be effective in reducing interstage mortality and
for that reason has been introduced in many centers to opti-
mize the patient’s safety in the ambulant setting [12].
In the past decade, studies have compared both treatment
options [3, 19, 22], but to date, prospectively collected data
on interstage morbidity and mortality of infants after the
Norwood and hybrid procedures are limited. We reviewed
the clinical course, the outcomes, and the characteristics of
the subjects enrolled in the interstage monitoring program.
Outcome was defined as mortality and morbidity, including
rehospitalization and need for reinterventions.
Patients and Methods
Study Design
We conducted a longitudinal observational study of the
clinical courses and outcomes of patients undergoing the
interstage home monitoring program after the Norwood I
and hybrid procedure for infants with variants of HLHS.
Study Population
Since October 2008 and December 2011, all infants with
HLHS and other univentricular heart malformations with
aortic arch anomaly have been scheduled to undergo inter-
stage monitoring after the Norwood I and hybrid procedures.
Interstage Monitoring
Our standardized program of interstage home monitoring
was adopted from former published protocols [12, 13, 15].
Parents were taught by specialized nurses to recognize
symptoms of deterioration such as poor feeding, increased
sweating, dyspnea, tachypnea, edema, and irritability.
Furthermore, the parents were taught to detect failure to
thrive and deterioration of systemic oxygenation and to
perform daily measurements of body weight and transcu-
taneous oxygen saturation (tcSO2). Measurement of body
weight was recommended once per day at the same time
point before feeding (at about noontime).
For measurement of tcSO2, we used a small handheld
pulse oximeter (Rad-5; Masimo Co., Irvine, CA, USA).
Measurements were performed three times per day at
comparable time points in the morning, at noon, and in the
evening. The sensor was placed around the same hand, and
tcSO2 values were noted when the infant was calm and
signal intensity was good. The values of body weight and
tcSO2 were noted in a protocol given to the parents after
detailed instructions before discharge of the infants from
the hospital. The red flags of interstage monitoring were
defined as (1) loss of body weight exceeding 50 g within
2 days or gain in body weight less than 20 g or more than
150 g for two consecutive days, and (3) tcSO2 values lower
than 70 % or higher than 85 % or those otherwise prede-
fined individually by the pediatric cardiologist before the
infant’s discharge from the hospital.
Parents were instructed to contact the staff pediatric
cardiologist of our hospital immediately for rehospitaliza-
tion aimed at an urgent diagnostic workup in case of red
flags during interstage monitoring. Clinical visits were
routinely performed every 2 weeks either by the staff
pediatric cardiologist of our hospital or by the individual
outpatient pediatric cardiologist.
Clinical Course
Morbidity was defined as the need for rehospitalization and
reintervention and included cases of red flags during
interstage monitoring. Cardiac diagnoses were made by an
experienced cardiologist based on findings in echocardi-
ography, cardiac catheterization, and cardiac magnetic
resonance imaging.
Ethics
Ethical approval for the study and data collection was
obtained according to the guidelines of the local ethics
committee.
Statistical Analysis
For descriptive statistics, values are shown as median with
range. Differences between the treatment groups were
tested using Fisher’s exact test for categorical variables and
an exact Mann–Whitney U test for quantitative variables.
Results
Patients
Between June 2008 and December 2011, 26 infants (14
boys) with classical HLHS (n = 16) and its variants
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(functional hypoplastic left heart complex), including uni-
ventricular heart malformations with aortic arch anomaly
(n = 10), were scheduled for interstage monitoring. The
cardiac diagnoses of the patients with variants of hypo-
plastic left heart included double-outlet right ventricle (n =
4), double-inlet left ventricle (n = 2), dysbalanced atrio-
ventricular septal defect (n = 2), and borderline hypo-
plastic left heart with left ventricular outflow tract
obstruction (n = 2). Of the 26 infants, 12 were treated by
the Norwood I procedure and 14 by the hybrid procedure.
The infants treated by the Norwood I procedure received
the modified Blalock–Taussig (BT) shunt (n = 7) or the
right ventricle-to pulmonary artery (Sano) shunt (n = 5).
The median age at first-stage palliation was 8 days
(range 1–36 days). The infants undergoing the hybrid
procedure were younger at first-stage palliation (age,
4 days; range 1–17) than those undergoing the Norwood
procedure (age, 9 days; range 3–36 days) (p = 0.02). The
median day at second-stage palliation, if performed, was
99 days (range 48–190 days). These values did not differ
between the Norwood and hybrid procedures (p = 0.44).
The clinical course after first-stage palliation, with either
the hybrid or Norwood procedure, is depicted in Fig. 1.
Mortality
Three infants (11.5 %) died after first-stage palliation. One
patient died after the hybrid procedure at the hospital before
discharge (at age 44 days), and two patients died after the
Norwood I procedure, either before discharge at the hospital (at
age 90 days) or after discharge at home (at age 33 days; Fig. 1).
Three infants (11.5 %) died after second-stage pallia-
tion. Two patients in the hybrid group died after compre-
hensive stage 1 or 2 palliation at the hospital before
discharge, one early (at age 124 days) and one late (at age
10.4 months). One patient in the Norwood group died early
after Norwood II (at age 106 days). Whether infants died
after first- or second-stage palliation or survived did not
differ between the treatment groups (p = 0.83).
All the patients in the Norwood group who died were
treated primarily with a BT shunt. For all the patients who
died after second-stage palliation, the time until the second
Fig. 1 Overview of the clinical course and interstage monitoring of infants with hypoplastic left heart syndrome treated by the hybrid and
Norwood procedures
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stage was less than 90 days. The Norwood I and hybrid
procedures did not differ in terms of mortality rate (23 %;
p = 1.00).
Morbidity
Seven infants (26.9 %) could not be discharged from the
hospital due to hemodynamic instability and were referred
for early second-stage palliation (\90 days) (Fig. 1). After
first-stage palliation, the invasive reevaluation rate before
discharge was high, with cardiac catheterizations needed
for 14 patients (53.8 %; eight hybrid and six Norwood
patients; p = 0.69).
Catheter reinterventions became necessary for eight
infants (30.7 %; five hybrid and three Norwood patients;
p = 0.22). These eight reinterventions included stenting of
the left pulmonary artery (n = 1), residual aortic coarcta-
tion (n = 1), and stenosis of the Sano shunt (n = 1) in
infants after the Norwood procedure, as well as balloon
dilation of pulmonary artery banding (n = 3) and balloon
dilation and/or stenting of atrial septal defect (n = 2) in
infants after the hybrid procedure.
Surgical reinterventions were necessary for three infants
(11.5 %) including enlargement of residual aortic coarc-
tation (n = 1; after the Norwood procedure) and rebanding
of pulmonary artery side branches (n = 2; after the hybrid
procedure) (p = 1.00).
Interstage Monitoring
Only 14 of the 26 infants could be discharged from the
hospital and received interstage monitoring for a period of
89 days (range 10–177 days) (Fig. 1). One of the two
additional infants scheduled for interstage monitoring
received home monitoring until the end of the study period
(to date, without red flags), and the family of the other
infant did not perform interstage monitoring (Fig. 1).
One infant (3.9 %) died during interstage monitoring
after the Norwood procedure. We found a breach of the
physiologic criteria for interstage monitoring in 50 % of
the infants (n = 7, comprising five hybrid and two Nor-
wood patients) after 10 days (range 4–68 days).
The red flags for interstage monitoring included lower
oxygen saturation (n = 6); clinical signs of congestive
heart failure including poor feeding, sweating, dyspnea,
tachypnea, and sudden malaise with episodes of irritability
(n = 4); and excessive body weight gain (n = 1). All the
red flag events of interstage monitoring led to rehospitali-
zation within 48 h and cardiac catheterization for six
infants (four hybrid and two Norwood infants; p = 0.39),
requiring interventions for two infants (PDA stent dilation
or ASD stenting, all for hybrid patients). Three of the seven
patients with red flag events of interstage monitoring were
candidates for an early second-stage surgery.
Discussion
Infants with HLHS and its functional variants are at risk for
a complicated clinical course including severe morbidity,
or even interstage mortality, after first-stage palliation by
the Norwood or hybrid procedure. Reinterventions either
by cardiac catheterization or by cardiac surgery were
common in both treatment groups. Remarkably, only 3 of
the 26 patients (two after the hybrid procedure and one
after the Norwood procedure) experienced a completely
uneventful clinical course without the need for reinter-
vention, leading to successful second-stage palliation with
a fairly good outcome.
In our cohort, the number of patients not discharged
after first-stage palliation was relatively high (26.9 %),
leading to earlier timing of second-stage palliation. Nev-
ertheless, the Norwood and hybrid procedures did not
differ in overall mortality. Previous studies have described
early second-stage palliation as associated with risk factors
for interstage mortality including reduced pulmonary artery
growth, elevated pulmonary vascular resistance, and
reduced myocardial function associated with atrioventric-
ular valve regurgitation [2, 14]. On the other hand, the
early timing of second-stage palliation may reflect a sicker
phenotype of HLHS interacting with a higher rate of per-
ioperative complications.
Before the first discharge from the hospital, an invasive
reevaluation with cardiac catheterization became necessary
for more than half of the patients (53.8 %). Catheter rein-
terventions were indicated for both the hybrid and Nor-
wood procedures (30.7 %). Surgical reinterventions
became necessary less frequently but also were comparable
between the two treatment groups (11.5 %).
As described by previous publications, the complica-
tions in the current study included vascular stenosis of the
left pulmonary artery, residual aortic coarctation, and ste-
nosis of the right ventricle-to-pulmonary artery (Sano)
shunt. Also as described previously [5, 7, 9], we were able
to treat these complications successfully by endovascular
stent implantation. Suboptimal banding of the pulmonary
branch artery was treated by surgical revision.
Even if discharge from hospital is reasonable, the risk of
adverse events remains high but can be sufficiently detec-
ted by interstage monitoring. If a breach of physiologic
criteria for interstage monitoring occurs, we prefer invasive
reevaluation with cardiac catheterization. Otherwise, we
could find no other conclusive explanation. This led to a
considerable number of catheter reinterventions.
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Additionally, monitoring data serve as part of the clin-
ical decision-making process together with hemodynamic
findings obtained by cardiac catheterization. To date, no
significant difference has been detectable between patients
treated by the Norwood procedure and those treated by the
hybrid procedure, only a trend toward more red flag
interstage monitoring events and more reinterventions for
patients after the hybrid procedure. Further multicenter
studies are necessary to determine whether this difference,
which may be attributable to the circumstance of ongoing
retrograde aortic flow in patients after the hybrid proce-
dure, can be confirmed.
One single patient of our cohort died despite red flag
events of interstage monitoring at home after the Norwood
procedure with a BT shunt at the age of 33 days. After red
flag events of interstage monitoring, this patient was
transferred immediately to the local children’s hospital,
where sudden hemodynamic collapse with impossibility of
successful resuscitation occurred directly after arrival. Due
to the geographic distance to the primary treating cardiac
center, no further support, including options of assist
devices, was available. The exact cause of death remained
unexplained, but as described in the literature, BT shunt
might have been a risk factor for this patient [14, 20].
The overall interstage mortality at home in our cohort
was 7.1 %. This number is well within the range of inter-
stage mortality (0–22 %) described in the literature [12, 15,
21].
The high number of red flag interstage events in our
cohort shows clearly that interstage home monitoring is a
valuable and substantial part of the treatment program for
patients with HLHS. Interstage monitoring for patients
with HLHS provides a sensitive surveillance of physiologic
instability and facilitates early recognition of signs denot-
ing clinical deterioration.
Although the risk factors for interstage mortality remain
multifactorial and are most often not modifiable, the goal
of interstage monitoring is effective detection of potentially
harmful constellations such as a simple intercurrent illness,
fever, or dehydration, which might destabilize the patient at
risk. This also includes detailed extensive parental educa-
tion long before discharge to teach parents about signs and
symptoms to be monitored, written guidelines, when to
contact our hospital, and clear detailed guidelines for the
outpatient cardiologist and pediatrician to ensure emergent
admission in case of red flag interstage monitoring events.
Further approaches for interstage monitoring have
recently been described in the literature including weekly
telephone contact by high-risk cardiac nurse practitioners
and use of telemedicine devices or smartphone apps [6, 8,
18]. Future research is needed to determine the psychoso-
cial impact of interstage monitoring on the family itself,
affecting family stress and quality of life [16, 23].
Study Limitations
Of course, the overall number of patients in this study was
small, limiting further statistical analysis, especially for
those patients being discharged from hospital. Furthermore,
the study period was part of a learning curve regarding
technical aspects of optimizing interventional and surgical
therapy such as grading of pulmonary artery banding after
the hybrid procedure and stenosis of the left pulmonary
artery after the Norwood procedure.
Conclusions
Morbidity among infants after first-stage surgery before
discharge is characterized by a high reintervention rate
(30.7 %) independent of the surgical approach. Despite
retrograde aortic flow in infants with HLHS after the
hybrid procedure, the mortality rates were comparable
between the two groups. Mortality after second-stage sur-
gery occurred with an early age at second-stage palliation
(\90 days). After discharge, we found a breach of physi-
ologic criteria for interstage monitoring in 50 % of the
patients, indicating the need for catheter treatment for
29 % of the patients. This highlights the importance of
interstage monitoring in both treatment groups.
References
1. Akintuerk H, Michel-Behnke I, Valeske K, Mueller M, Thul J,
Bauer J, Hagel KJ, Kreuder J, Vogt P, Schranz D (2002) Stenting
of the arterial duct and banding of the pulmonary arteries: basis
for combined Norwood stage 1 and 2 repair in hypoplastic left
heart. Circulation 105:1099–1103
2. Ashburn DA, McCrindle BW, Tchervenkov CI, Jacobs ML,
Lofland GK, Bove EL, Spray TL, Williams WG, Blackstone EH
(2003) Outcomes after the Norwood operation in neonates with
critical aortic stenosis or aortic valve atresia. J Thorac Cardiovasc
Surg 125:1070–1082
3. Baba K, Kotani Y, Chetan D, Chaturvedi RR, Lee KJ, Benson
LN, Grosse-Wortmann L, Van Arsdell GS, Caldarone CA, Honjo
O (2012) Hybrid versus Norwood strategies for single-ventricle
palliation. Circulation 126:S123–S131
4. Barron DJ, Kilby MD, Davies B, Wright JG, Jones TJ, Brawn WJ
(2009) Hypoplastic left heart syndrome. Lancet 374:551–564
5. Brown DW, Gauvreau K, Moran AM, Jenkins KJ, Perry SB, del
Nido PJ, Colan SD (2003) Clinical outcomes and utility of car-
diac catheterization prior to superior cavopulmonary anastomo-
sis. J Thorac Cardiovasc Surg 126:272–281
6. Cross R, Steury R, Randall A, Fuska M, Sable C (2012) Single-
ventricle palliation for high-risk neonates: examining the feasi-
bility of an automated home monitoring system after stage I
palliation. Future Cardiol 8:227–235
7. Dahnert I, Riede FT, Razek V, Weidenbach M, Rastan A, Wal-
ther T, Kostelka M (2007) Catheter interventional treatment of
Sano shunt obstruction in patients following modified Norwood
Pediatr Cardiol (2014) 35:851–856 855
123
palliation for hypoplastic left heart syndrome. Clin Res Cardiol
96:719–722
8. Dobrolet NC, Nieves JA, Welch EM, Khan D, Rossi AF, Burke
RP, Zahn EM (2011) New approach to interstage care for palli-
ated high-risk patients with congenital heart disease. J Thorac
Cardiovasc Surg 142:855–860
9. Eicken A, Schreiber C (2006) Stenting of a stenosed Sano shunt
after palliation in hypoplastic left heart syndrome. Ann Thorac
Surg 82:1168–1169 author reply 1169
10. Feinstein JA, Benson DW, Dubin AM, Cohen MS, Maxey DM,
Mahle WT, Pahl E, Villafane J, Bhatt AB, Peng LF, Johnson BA,
Marsden AL, Daniels CJ, Rudd NA, Caldarone CA, Mussatto
KA, Morales DL, Ivy DD, Gaynor JW, Tweddell JS, Deal BJ,
Furck AK, Rosenthal GL, Ohye RG, Ghanayem NS, Cheatham
JP, Tworetzky W, Martin GR (2012) Hypoplastic left heart
syndrome: current considerations and expectations. J Am Coll
Cardiol 59:S1–S42
11. Galantowicz M, Cheatham JP (2005) Lessons learned from the
development of a new hybrid strategy for the management of
hypoplastic left heart syndrome. Pediatr Cardiol 26:190–199
12. Ghanayem NS, Hoffman GM, Mussatto KA, Cava JR, Frommelt
PC, Rudd NA, Steltzer MM, Bevandic SM, Frisbee SS, Jaquiss
RD, Litwin SB, Tweddell JS (2003) Home surveillance program
prevents interstage mortality after the Norwood procedure.
J Thorac Cardiovasc Surg 126:1367–1377
13. Ghanayem NS, Cava JR, Jaquiss RD, Tweddell JS (2004) Home
monitoring of infants after stage one palliation for hypoplastic
left heart syndrome. Semin Thorac Cardiovasc Surg Pediatr Card
Surg Annu 7:32–38
14. Ghanayem NS, Allen KR, Tabbutt S, Atz AM, Clabby ML,
Cooper DS, Eghtesady P, Frommelt PC, Gruber PJ, Hill KD,
Kaltman JR, Laussen PC, Lewis AB, Lurito KJ, Minich LL, Ohye
RG, Schonbeck JV, Schwartz SM, Singh RK, Goldberg CS
(2012) Interstage mortality after the Norwood procedure: results
of the Multicenter Single-Ventricle Reconstruction Trial. J Tho-
rac Cardiovasc Surg 144:896–906
15. Hansen JH, Furck AK, Petko C, Buchholz-Berdau R, Voges I,
Scheewe J, Rickers C, Kramer HH (2012) Use of surveillance
criteria reduces interstage mortality after the Norwood operation
for hypoplastic left heart syndrome. Eur J Cardiothorac Surg
41:1013–1018
16. Hartman DM, Medoff-Cooper B (2012) Transition to home after
neonatal surgery for congenital heart disease. MCN Am J Matern
Child Nurs 37:95–100
17. Mahle WT, Spray TL, Wernovsky G, Gaynor JW, Clark BJ III
(2000) Survival after reconstructive surgery for hypoplastic left
heart syndrome: a 15-year experience from a single institution.
Circulation 102:136–141
18. McCrossan B, Morgan G, Grant B, Sands AJ, Craig BG, Doherty
NN, Agus AM, Crealey GE, Casey FA (2012) A randomised trial
of a remote home support programme for infants with major
congenital heart disease. Heart 98:1523–1528
19. Miller-Tate H, Stewart J, Allen R, Husain N, Rosen K, Cheatham
JP, Galantowicz M, Cua CL (2012) Interstage weight gain for
patients with hypoplastic left heart syndrome undergoing the
hybrid procedure. Congenit Heart Dis 8(3):228–233
20. Ohye RG, Sleeper LA, Mahony L, Newburger JW, Pearson GD,
Lu M, Goldberg CS, Tabbutt S, Frommelt PC, Ghanayem NS,
Laussen PC, Rhodes JF, Lewis AB, Mital S, Ravishankar C,
Williams IA, Dunbar-Masterson C, Atz AM, Colan S, Minich LL,
Pizarro C, Kanter KR, Jaggers J, Jacobs JP, Krawczeski CD, Pike
N, McCrindle BW, Virzi L, Gaynor JW (2010) Comparison of
shunt types in the Norwood procedure for single-ventricle lesions.
N Engl J Med 362:1980–1992
21. Petit CJ, Fraser CD, Mattamal R, Slesnick TC, Cephus CE,
Ocampo EC (2011) The impact of a dedicated single-ventricle
home-monitoring program on interstage somatic growth, inter-
stage attrition, and 1-year survival. J Thorac Cardiovasc Surg
142:1358–1366
22. Photiadis J, Sinzobahamvya N, Hraska V, Asfour B (2012) Does
bilateral pulmonary banding in comparison to Norwood proce-
dure improve outcome in neonates with hypoplastic left heart
syndrome beyond second-stage palliation? A review of the cur-
rent literature. Thorac Cardiovasc Surg 60:181–188
23. Sarajuuri A, Lonnqvist T, Schmitt F, Almqvist F, Jokinen E
(2012) Patients with univentricular heart in early childhood:
parenting stress and child behaviour. Acta Paediatr 101:252–257
24. Wernovsky G, Kuijpers M, Van Rossem MC, Marino BS, Ravi-
shankar C, Dominguez T, Godinez RI, Dodds KM, Ittenbach RF,
Nicolson SC, Bird GL, Gaynor JW, Spray TL, Tabbutt S (2007)
Postoperative course in the cardiac intensive care unit following the
first stage of Norwood reconstruction. Cardiol Young 17:652–665
856 Pediatr Cardiol (2014) 35:851–856
123
